Jul 30 |
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
Jul 29 |
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
|
Jul 29 |
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
|
Jul 29 |
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
Jul 28 |
Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns climbed after last week's 6.1% gain, institutional investors must be happy
|
Jul 27 |
A Look At Gilead Sciences After Its Recent Weakness
|
Jul 25 |
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
|
Jul 25 |
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
Jul 25 |
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
|
Jul 25 |
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
|